OakChart

Cns Pharmaceuticals Inc

CNSPHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

3.62-0.23 (-5.97%)
2026-11-12 05:26 CET
Market cap
5.29 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-16.70 USD m
Free cash flow, TTM
-13.44 USD m
EPS diluted, TTM
-23.59
P/E
-
Compare

Price

CNSP against its 20, 50 and 200-day averages
2050200missearnings
4.006.008.00477K954KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CNSPclose 3.6220-day 4.5850-day 5.10200-day 4.503.62

65.7% under the 52-week high of 10.54 on 4 May 2026. 52-week low 1.90 on 22 Apr 2026. Last 15 sessions, 50.6% high to low

Volume 0.45× normal · the line is the 50-bar volume average

Profile

CNSP
52-week range, 20% of the way up
1.9010.54

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Employees8
IPONov 08, 2019
Beta1.02
ATR, 14d0.49
Rel volume0.45
Short float0.11%
Insider own1.44%
Inst own19.10%

Snapshot

6 groups

Valuation

Index-
Market Cap5.29M
Enterprise Value-14.69M
Income-16.70M
Sales0.00M
Book/sh12.45
Cash/sh13.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPONov 08, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.29
P/C0.26
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.85
Current Ratio5.85
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-23.59
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y95.26% 85.25%
Sales past 3/5Y- -
EPS Y/Y TTM88.43%
Sales Y/Y TTM-
EPS Q/Q94.10%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.-58.33% -

Ownership

Insider Own1.44%
Insider Trans76.14%
Inst Own19.10%
Inst Trans5.20%
ROA-91.64%
ROE-106.62%
ROIC-91.75%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-20.89%
SMA50-29.01%
SMA200-19.53%
Trades-

Technical

Shs Outstand1.46M
Shs Float1.44M
Short Float0.11%
Short Ratio0.17
Short Interest0.00M
52W High10.54 -65.65%
52W Low1.90 90.53%
Volatility7.44% 12.74%
ATR (14)0.49
RSI (14)31.78
Beta1.02
Rel Volume0.45
Avg Volume9.79K
Volume4,376

Performance

Perf Week-16.59%
Perf Month-32.34%
Perf Quarter-29.71%
Perf Half Y-34.42%
Perf YTD-31.05%
Perf Year-46.21%
Perf 3Y-99.99%
Perf 5Y-100.00%
Perf 10Y-
Recom1.00
Target Price10.00
Prev Close3.85
Price3.62
Change %-5.97%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Dec 28, 2020DowngradeLLadenburg ThalmannBuy → Neutral
Aug 24, 2020InitiatedLLadenburg ThalmannBuy$11+203.9%

Peers

Mkt cap
TickerCompanyMkt cap
MBRXMoleculin Biotech Inc8.50M
KZIAKazia Therapeutics Limited ADR84.92M
NTHINeOnc Technologies Holdings Inc130.41M
BDRXBiodexa Pharmaceuticals Plc ADR1.25M
LTRNLantern Pharma Inc7.19M
ACTUActuate Therapeutics Inc16.63M
BYSIBeyondSpring Inc26.48M
CRDFCardiff Oncology Inc59.54M
ONCOOnconetix Inc2.21M
IMRXImmuneering Corp245.45M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Fisher MichalDirectorMay 18 '26Buy5.002,00010,0002,000Aug 18 09:01 AM
Charles Faith L.DirectorMay 18 '26Buy4.797,10034,0027,100May 20 09:03 AM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth (ACCESSWIRE)
  • CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference (ACCESSWIRE)
  • CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation (ACCESSWIRE) -8.91%
  • CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment (ACCESSWIRE)
  • CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress (ACCESSWIRE) -9.24%
  • BC-Most Active Stocks (Associated Press) +239.23%
  • CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing (ACCESSWIRE)
  • CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline (ACCESSWIRE) -11.64%
  • CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team (ACCESSWIRE)
  • CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation (ACCESSWIRE) -5.78%
  • CNS Pharmaceuticals Issues Letter to Shareholders (ACCESSWIRE)
  • CNS Pharmaceuticals Announces CEO Transition (ACCESSWIRE) -6.40%
  • CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
  • CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting (ACCESSWIRE)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.380-0.240-0.2400.00-1
2026Q12026-05-14-7.300-5.370-8.8200.00-1
2025Q42026-02-25-5.090-5.090-10.1530.00-1
2025Q32025-11-12-5.760-6.630-5.7590.00-1
2025Q22025-08-14-6.420-9.600-6.4170.00-1
2025Q12025-05-15-18.960-24.000-18.9300.00-1
2024Q42025-03-31-447.96-87.960-26.9640.00-2
2024Q32024-11-14-150-60.000-151.640.00-1
2024Q22024-08-12-4,032--4,0320.00--
2023Q32023-11-16-32,400--32,4830.00--
2023Q22023-08-14-31,200-84,600-31,114--1
2023Q12023-05-15-77,700--77,608---
2022Q32022-11-14-72,000-72,000-76,8780.000.001
2021Q32022-11-12-126,000--125,0910.00-3
2022Q22022-08-15-81,000-54,000-80,1720.00-1
2022Q12022-05-16-63,000-72,000-64,5750.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-252,000--212,1210.00-
2020FY-513,000-452,250-512,2080.000.00
2021FY-477,000-535,500-495,027-0.00
2022FY-336,600--336,5000.00-
2024FY-466.44-495.48-466.440.00-
2025FY-35.750-27.430-35.7500.00-
2026FY--1.650---
2027FY--1.660---
2028FY--1.880---
2029FY--1.990---
2030FY-2.280--77.32

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3R2026-08-13100-0.27-0.27-0.27
2026Q3R2026-07-28100-0.27-0.27-0.27
2026Q3R2026-05-14110-0.27-0.27-0.27
2026Q3R2026-03-04110-0.74-0.74-0.74
2026Q3R2026-02-25100-1.33-1.33-1.33
2026Q3R2026-02-01100-1.33-1.33-1.33
2026Q3R2025-11-18110-1.33-1.33-1.33
2026Q3R2025-11-12100-1.35-1.35-1.35
2026Q3R2025-11-11100-1.35-1.35-1.35
2026Q3R2025-11-10100-1.35-1.35-1.35
2026Q3R2025-11-09100-1.35-1.35-1.35
2026Q3R2025-11-08100-1.35-1.35-1.35
2026Q3R2025-11-07100-1.35-1.35-1.35
2026Q3R2025-11-06100-1.35-1.35-1.35

Estimate history

EPS, annual-11997-404415-212121-512208.001-495027.001-336499.5-150114.3-466.44-35.75-23.5914
Period201720182019202020212022202320242025TTM
EPS, quarterly-4031.544-151.644-26.964-18.93-6.417-5.759-10.153-7.302-0.379
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00000000.1180.6331.461
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.0020.0560.1180.2450.5040.5750.6330.8111.461
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.000.000.000.010.010.010.000.00
Gross Profit-0.01-0.00-0.00-0.00-0.01-0.01-0.01-0.000.00
Selling, General and Administrative Excl. Other16.9015.9814.9018.8614.9214.479.443.830.88
Research and Development10.119.779.2914.109.309.815.061.850.02
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-16.91-15.99-14.90-18.87-14.93-14.49-9.45-3.83-0.88
Interest Expense0.010.020.020.010.010.010.000.040.05
Unusual Expense0.000.000.000.000.330.000.000.006.41
Net Income Before Taxes-16.70-15.85-14.86-18.85-15.27-14.50-9.46-3.88-7.39
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-16.70-15.85-14.86-18.85-15.27-14.50-9.46-3.88-7.39
Net Income From Continuing Operations-16.70-15.85-14.86-18.85-15.27-14.50-9.46-3.88-7.39
Net Income-16.70-15.85-14.86-18.85-15.27-14.50-9.46-3.88-7.39
EPS (Recurring)-2.44-35.75-466.44-150,114.40-331,346.74-495,025.46-512,207.13-212,124.03-158,968.17
EPS (Basic, Before Extraordinaries)-23.59-35.75-466.44-150,114.30-336,499.50-495,027.00-512,208.00-212,121.00-404,415.00
EPS (Diluted)-23.59-35.75-466.44-150,114.30-336,499.50-495,027.00-512,208.00-212,121.00-404,415.00
EBITDA-16.90-15.98-14.90-18.86-14.92-14.47-9.44-3.83-0.88
Non-Operating Income (Expense)0.230.150.060.030.000.000.000.00-0.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.110.190.841.011.201.721.290.480.10
Shares Outstanding1.460.630.120.000.000.000.000.000.00
Market Capitalization5.295.298.515.343.2019.6242.4664.9863.66

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.000.000.000.000.000.000.00
Gross Profit-0.01-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Selling, General and Administrative Excl. Other2.694.975.993.252.414.343.205.63
Research and Development1.203.543.172.201.173.241.504.24
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.70-4.98-5.99-3.25-2.41-4.34-3.20-5.63
Interest Expense0.000.010.000.000.000.010.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-2.59-4.94-5.96-3.22-2.37-4.30-3.18-5.61
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.59-4.94-5.96-3.22-2.37-4.30-3.18-5.61
Net Income From Continuing Operations-2.59-4.94-5.96-3.22-2.37-4.30-3.18-5.61
Net Income-2.59-4.94-5.96-3.22-2.37-4.30-3.18-5.61
EPS (Recurring)-0.38-7.30-10.15-5.76-6.42-18.93-26.96-151.64
EPS (Basic, Before Extraordinaries)-0.38-7.30-10.15-5.76-6.42-18.93-26.96-151.64
EPS (Diluted)-0.38-7.30-10.15-5.76-6.42-18.93-26.96-151.64
EBITDA-2.69-4.97-5.99-3.25-2.41-4.34-3.20-5.63
Non-Operating Income (Expense)0.120.040.030.040.040.040.030.03
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.000.090.020.020.060.130.82
Shares Outstanding1.460.810.630.570.500.250.120.06
Market Capitalization5.291.483.265.174.994.008.514.36

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.206.460.5510.065.0014.047.240.560.11
Short Term Receivables0.000.880.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.861.290.842.512.471.460.650.030.05
Total Current Assets8.068.641.3912.567.4815.507.890.590.16
Net Property, Plant & Equipment0.020.010.000.010.020.020.020.000.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.550.060.310.481.260.330.000.100.00
Total Assets8.628.701.7013.058.7615.857.910.680.16
Short Term Debt Incl. Current Port. of LT Debt0.330.330.300.410.390.440.000.320.12
Accounts Payable3.772.205.833.681.980.950.290.130.06
Other Current Liabilities-0.00-0.00-0.000.830.220.520.020.790.04
Total Current Liabilities4.102.526.134.922.591.910.311.230.22
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.000.000.00
Total Liabilities4.102.526.134.922.591.910.311.230.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4.526.18-4.438.136.1613.957.60-0.55-0.06
Total Shareholders Equity4.526.18-4.438.136.1613.957.60-0.55-0.06
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity4.526.18-4.438.136.1613.957.60-0.55-0.06
Total Liabilities & Stockholders Equity8.628.701.7013.058.7615.857.910.680.16
Book Value Per Share7.1552.43-21,395.34150,857.55194,819.74526,203.31415,858.43-30,052.35-3,202.31
Tangible Book Value Per Share7.1552.43-21,395.34150,857.55194,819.74526,203.31415,858.43-30,052.35-3,202.31
Full-Time Employees8555555--
Price to Book Ratio0.291.38-3.070.382.963.048.55294,733.39-
Return on Assets-182.99-285.68-255.54-140.06-117.80-79.59-90.22-1,748.47-
Return on Equity-296.30-1,703.39-1,018.78-207.04-144.15-87.78-109.96--
Return on Invested Capital-350.48-240.55--187.81-235.19-67.81-51.01--
Quick Ratio1.963.420.232.552.888.1325.380.480.73
Current Ratio1.963.420.232.552.888.1325.380.480.73

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-16.70-15.85-14.86-18.85-15.27-14.50-9.46-3.88-7.39
Depreciation0.010.000.000.000.010.010.010.00-
Other Funds (Non Cash)0.110.191.441.011.541.721.290.756.59
Funds from Operations-16.57-15.66-13.42-17.84-13.72-12.76-8.15-3.13-0.80
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.161.85-3.693.703.16-0.780.83-0.430.08
Cash from Operating Activities-13.41-13.81-17.11-14.14-10.56-13.54-7.32-3.55-0.72
Capital Expenditures-0.03-0.02-0.00-0.00-0.00-0.01-0.02-0.020.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.03-0.02-0.00-0.00-0.00-0.01-0.02-0.020.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock21.6513.9923.335.0816.044.9914.1810.290.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock21.6513.9923.335.0816.044.9914.1810.290.39
Proceedsfrom Stock Options21.6513.9823.312.1116.044.6514.1810.290.39
Issuance or Reduction of Debt, Net-0.31-0.30-0.30-0.44-0.43-0.48-0.04-0.040.18
Change in Long Term Debt0.000.000.000.000.000.00-0.04-0.040.18
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.28
Reduction of Long Term Debt0.000.000.000.000.000.00-0.04-0.04-0.10
Net Financing Active Other Cash Flow-0.000.880.000.000.000.000.000.000.59
Other Financing Activities Uses-0.00-0.000.000.000.000.000.000.00-
Cash from Financing Activities21.3014.5723.034.6415.614.5114.1310.261.16
Net Change in Cash7.860.745.91-9.515.05-9.036.806.690.44
Free Cash Flow-13.44-13.83-17.12-14.14-10.56-13.54-7.34-3.57-0.72
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments19.982.957.209.8612.1313.05
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets1.861.100.861.481.990.65
Total Current Assets21.854.058.0611.3514.1213.70
Net Property, Plant & Equipment0.010.020.020.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.070.580.550.520.380.04
Total Assets21.944.658.6211.8714.5113.75
Short Term Debt Incl. Current Port. of LT Debt0.000.230.330.030.120.21
Accounts Payable3.744.353.771.931.262.57
Other Current Liabilities0.000.00-0.000.00-0.00-0.00
Total Current Liabilities3.744.584.101.961.382.78
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.744.584.101.961.382.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18.200.074.529.9113.1210.97
Total Shareholders Equity18.200.074.529.9113.1210.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.200.074.529.9113.1210.97
Total Liabilities & Stockholders Equity21.944.658.6211.8714.5113.75
Book Value Per Share12.450.097.1517.2526.0244.71
Tangible Book Value Per Share12.450.097.1517.2526.0244.71
Full-Time Employees--8---
Price to Book Ratio0.290.330.300.350.380.36
Return on Assets-91.64-179.17-182.99-135.60-182.11-202.65
Return on Equity-106.62-298.64-296.30-197.11-350.08-477.53
Return on Invested Capital-14.22-6,982.60-131.69-32.48-18.09-39.21
Quick Ratio5.850.881.965.7910.214.93
Current Ratio5.850.881.965.7910.214.93

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.59-4.94-5.96-3.22-2.37-4.30
Depreciation0.010.000.000.000.000.00
Other Funds (Non Cash)0.000.000.090.020.020.06
Funds from Operations-2.57-4.93-5.87-3.20-2.35-4.24
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.970.282.821.03-2.991.00
Cash from Operating Activities-3.54-4.65-3.05-2.17-5.34-3.24
Capital Expenditures-0.00-0.01-0.020.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.00-0.01-0.020.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock20.710.500.440.004.519.03
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock20.710.500.440.004.519.03
Proceedsfrom Stock Options20.710.500.440.004.519.03
Issuance or Reduction of Debt, Net-0.09-0.10-0.03-0.09-0.09-0.09
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.000.000.88
Other Financing Activities Uses0.000.000.00-0.000.00-0.00
Cash from Financing Activities20.580.400.41-0.094.439.83
Net Change in Cash17.03-4.25-2.66-2.27-0.926.59
Free Cash Flow-3.54-4.65-3.07-2.17--

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.11%0.0M1.4M9.37K
2026-10-150.09%0.0M1.4M6.53K
2026-09-300.06%0.0M1.4M7.28K
2026-09-150.21%0.0M1.4M9.00K
2026-08-310.15%0.0M1.4M11.50K
2026-08-140.87%0.0M1.5M30.26K
2026-07-310.78%0.0M1.5M1.40M
2026-07-151.09%0.0M1.5M1.43M
2026-06-302.50%0.0M1.5M1.41M
2026-06-152.67%0.0M1.5M1.39M
2026-05-293.35%0.0M1.5M1.42M
2026-05-152.11%0.0M1.5M1.40M
2026-04-30-0.0M-31.44K
2026-04-15-0.1M-33.78K
2026-03-31-0.1M-47.35K
2026-03-136.03%0.0M0.6M43.65K
2026-02-277.00%0.0M0.6M37.04K
2026-02-136.67%0.0M0.6M35.90K
2026-01-304.91%0.0M0.6M35.16K
2026-01-154.57%0.0M0.6M32.18K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-028-KCurrent report2026-09-30SEC
2026-08-25DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-21DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-30SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-183Initial statement of beneficial ownership of securities2026-05-04SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-028-KCurrent report2026-07-02SEC
2026-05-26EFFECTEffectiveness filing by commission orderSEC
2026-05-26424B3SEC
2026-05-22CORRESPSEC
2026-05-22UPLOADUpload SubmissionSEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-19DNotice of sales of securities on Form D (Regulation D)SEC
2026-05-19S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-04SEC
2026-04-3010-K/A2025-12-31SEC
2026-04-17SCHEDULE 13GSEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-118-KCurrent report2026-03-11SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-043Initial statement of beneficial ownership of securities2026-03-02SEC
2026-03-044Statement of changes in beneficial ownership of securities2026-03-02SEC
2026-03-043Initial statement of beneficial ownership of securities2026-03-02SEC
2026-03-028-KCurrent report2026-02-26SEC
2026-02-27S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-02-178-KCurrent report2026-02-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0544.00K200
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Ikarian Capital, LLC9.29%
ADAR1 Capital Management, LLC4.79%
Stonepine Capital Management, LLC2.84%
BOOTHBAY FUND MANAGEMENT, LLC0.93%
VANGUARD FIDUCIARY TRUST CO0.70%
VANGUARD CAPITAL MANAGEMENT LLC0.48%
Tower Research Capital LLC0.05%
UBS Group AG0.01%
FMR LLC0.00%
BARRETT & COMPANY, INC.0.00%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.57%
VANGUARD EXTENDED MARKET INDEX FUND0.48%
Fidelity Series Total Market Index Fund0.04%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CNSP. Cached 15 minutes.